Concepedia

Publication | Open Access

FOLFOXIRI <i>vs</i> FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

DOIFull Paper Access

17

Citations

38

References

2020

Year

Angélique Vienot, Hortense Chevalier, Clément Bolognini, Elisabeta Gherga, Élodie Klajer, Aurélia Meurisse, Marine Jary, Stéfano Kim, Christelle d’Engremont, Thierry Nguyen,
World Journal of Gastrointestinal Oncology

Abstract

FOLFOXIRI is feasible in L1 in patients with aPDAC but does not confer any therapeutic benefit as compared with FOLFIRINOX. The low hematological toxicity rates strengthened the relevance of primary prophylaxis with hematopoietic growth factors.

References

YearCitations

Page 1